Rituximab and Acute Retinal Necrosis in a Patient with Scleromalacia and Rheumatoid Arthritis

BACKGROUNDRituximab is a widely used biologic agent, which has shown favourable results in the treatment of vasculitis. But immunosuppressive treatment also bears the risk of severe complications.METHODSA patient with rheumatoid arthritis, progressive scleromalacia, and acute retinal necrosis on the...

Full description

Saved in:
Bibliographic Details
Published inOcular immunology and inflammation Vol. 24; no. 1; pp. 96 - 98
Main Authors Schuler, Sarah, Brunner, Matthias, Bernauer, Wolfgang
Format Report
LanguageEnglish
Published 01.01.2016
Online AccessGet full text

Cover

More Information
Summary:BACKGROUNDRituximab is a widely used biologic agent, which has shown favourable results in the treatment of vasculitis. But immunosuppressive treatment also bears the risk of severe complications.METHODSA patient with rheumatoid arthritis, progressive scleromalacia, and acute retinal necrosis on therapy with rituximab is reported.RESULTSFor the first time, a correlation between rituximab and acute retinal necrosis in a patient with progressive rheumatoid scleromalacia is shown.CONCLUSIONSAlthough rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of acute retinal necrosis.
Bibliography:ObjectType-Case Study-3
ObjectType-Correspondence-1
content type line 59
SourceType-Reports-1
ObjectType-Report-2
ISSN:1744-5078
DOI:10.3109/09273948.2014.999377